1
van Oort, S, Rutters, F, Warlé-van Herwaarden, M F, Schram, M T, Stehouwer, C D, Tack, C J, Abbink, E J, Wolffenbuttel, B H, van der Klauw, M M, DeVries, J H, Siegelaar, S E, Sijbrands, E J, Özcan, B, de Valk, H W, Silvius, B, Schroijen, M A, Jazet, I M, van Ballegooijen, A J, Beulens, J W J, Elders, P J, Kramers, C
Veröffentlicht in: Diabetes Pearl from the Parelsnoer Initiative , van Oort , S , Rutters , F , Warlé-van Herwaarden , M F , Schram , M T , Stehouwer , C D , Tack , C J , Abbink , E J , Wolffenbuttel , B H , van der Klauw , M M , DeVries , J H , Siegelaar , S E , Sijbrands , E J , Özcan , B , de Valk , H W , Silvius , B , Schroijen , M A , Jazet , I M , van Ballegooijen , A J , Beulens , J W J , Elders , P J & Kramers , C 2021 , ' Characteristics associated with polypharmacy in people with type 2 diabetes : the Dutch Diabetes Pearl cohort ' , Diabetic Medicine , vol. 38 , no. 4 , e14406 . https://doi.org/10.1111/dme.14406;
2021
Veröffentlicht in: Diabetes Pearl from the Parelsnoer Initiative , van Oort , S , Rutters , F , Warlé-van Herwaarden , M F , Schram , M T , Stehouwer , C D , Tack , C J , Abbink , E J , Wolffenbuttel , B H , van der Klauw , M M , DeVries , J H , Siegelaar , S E , Sijbrands , E J , Özcan , B , de Valk , H W , Silvius , B , Schroijen , M A , Jazet , I M , van Ballegooijen , A J , Beulens , J W J , Elders , P J & Kramers , C 2021 , ' Characteristics associated with polypharmacy in people with type 2 diabetes : the Dutch Diabetes Pearl cohort ' , Diabetic Medicine , vol. 38 , no. 4 , e14406 . https://doi.org/10.1111/dme.14406;
2021